People
Oxurion NV announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
In the wake of a Complete Response Letter issued by the FDA, Trevana, Inc. is slashing one-third of its workforce. On Wednesday, Merrimack Pharmaceuticals also announced it was terminating 60 percent of its staff as the company narrows its research and development focus.
Mercaptor Discoveries announced today that Dr. Adriano Aguzzi, MD, PhD, is heading up the formation of its Scientific Advisory Board (SAB).
Tara Karimi, co-founder and chief executive officer of Cemvita, spoke with BioSpace about the company and the amazing things it’s working on to solve problems for human exploration to deep space by in-situ biomanufacturing of human life supplies.
Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”
The Medical Advertising Hall of Fame (MAHF) membership has elected its 2019 inductees: Carol DiSanto, trailblazer and former President of Cline, Davis & Mann, and Charlene Prounis, renowned entrepreneur co-founder of Flashpoint Medica and Accel Healthcare.
Biopharma companies make key appointments to fill leadership positions. Let’s take a look!
In an interview with S&P Global Market Intelligence, Alex Hoos, head of oncology at GSK, said the company could narrow its drug development focus to aim at products that will generate growth.
Noting advances in genetic manipulation and gene editing, the Food and Drug Administration announced a new Plant and Animal Biotechnology Innovation Action Plan.
PRESS RELEASES